Patents by Inventor Melanie K. Spriggs

Melanie K. Spriggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL RECEPTOR THAT BINDS CTLA-8
    Publication number: 20100233186
    Abstract: Isolated receptors for CTLA-8, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to inhibit an immune response.
    Type: Application
    Filed: March 11, 2010
    Publication date: September 16, 2010
    Inventors: ZHENGBIN YAO, MELANIE K. SPRIGGS, WILLIAM C. FANSLOW
  • Methods of inhibiting interleukin-17 receptor
    Publication number: 20090068737
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Application
    Filed: September 19, 2007
    Publication date: March 12, 2009
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Methods of treating asthma by administering interleukin-17 receptor
    Patent number: 7432237
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: October 7, 2008
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • CD40-Ligand lacking native-pattern glycosylation
    Patent number: 7405270
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: July 29, 2008
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, III, Melanie K. Spriggs
  • Mouse CD40 ligand-specific antibodies and hybridomas
    Patent number: 7309489
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: December 18, 2007
    Assignee: IMMUNEX Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
  • Methods of treating allergy by administering interleukin-17 receptor
    Patent number: 7273843
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: September 25, 2007
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Viral encoded semaphorin protein receptor DNA and polypeptides
    Patent number: 7214497
    Abstract: The invention is directed to VESPR polypeptides as a purified and isolated protein, the DNA encoding the VESPR polypeptide, host cells transfected with cDNAs encoding VESPR, and methods for preparing VESPR polypeptides.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: May 8, 2007
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Michael R. Comeau, Robert F. DuBose, Richard S. Johnson
  • Semaphorin polypeptides
    Publication number: 20040180825
    Abstract: The invention is directed to semaphorin polypeptide as a purified and isolated protein, the DNA encoding the semaphorin polypeptide, host cells transfected with cDNAs encoding the polypeptide and methods for preparing the semaphorin polypeptide.
    Type: Application
    Filed: December 19, 2003
    Publication date: September 16, 2004
    Applicant: Immunex Corporation
    Inventor: Melanie K. Spriggs
  • Methods of treating allergy by administering interleukin-17 receptor
    Publication number: 20040120899
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Application
    Filed: December 18, 2003
    Publication date: June 24, 2004
    Applicant: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Methods of treating asthma by administering interleukin-17 receptor
    Publication number: 20040120898
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Application
    Filed: December 18, 2003
    Publication date: June 24, 2004
    Applicant: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Methods of treating autoimmune disease by administering interleukin-17 receptor
    Patent number: 6680057
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: January 20, 2004
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • CD40-Ligand lacking native-pattern glycosylation
    Publication number: 20040006006
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.
    Type: Application
    Filed: July 19, 2002
    Publication date: January 8, 2004
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
  • Semaphorin polypeptides
    Patent number: 6670135
    Abstract: This invention provides a method comprising assaying the binding of a DCSema polypeptide to a VESPR protein.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: December 30, 2003
    Assignee: Immunex Corporation
    Inventor: Melanie K. Spriggs
  • Defective CD4+T-cells that express active CD40-L
    Patent number: 6613320
    Abstract: CD4+ cells obtained from individuals with defective CD40L gene and transfected with a vector containing CD40-L are described.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: September 2, 2003
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III, Michael B. Widmer, Barry L. Davison, Blair R. Renshaw
  • CD40-Ligand lacking native-pattern glycosylation
    Publication number: 20030144182
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.
    Type: Application
    Filed: July 19, 2002
    Publication date: July 31, 2003
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
  • Viral encoded semaphorin protein receptor DNA and polypeptides
    Publication number: 20030095968
    Abstract: The invention is directed to VESPR polypeptides as a purified and isolated protein, the DNA encoding the VESPR polypeptide, host cells transfected with cDNAs encoding VESPR, and methods for preparing VESPR polypeptides.
    Type: Application
    Filed: November 13, 2002
    Publication date: May 22, 2003
    Applicant: Immunex Corporation
    Inventors: Melanie K. Spriggs, Michael R. Comeau, Robert F. DuBose, Richard S. Johnson
  • METHODS OF TREATING AN UNDESIRED IMMUNE RESPONSE BY BLOCKING THE BINDING 0F CD40 LIGAND TO CD40
    Publication number: 20030091564
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Application
    Filed: August 2, 1999
    Publication date: May 15, 2003
    Inventors: RICHARD J. ARMITAGE, WILLIAM C. FANSLOW, MELANIE K. SPRIGGS, SUBHASHINI SRINIVASAN, MARYLOU G. GIBSON
  • Antibodies to viral encoded semaphorin protein receptor polypeptides
    Patent number: 6562949
    Abstract: The invention is directed to VESPR polypeptides as a purified and isolated protein, the DNA encoding the VESPR polypeptide, host cells transfected with cDNAs encoding VESPR, and methods for preparing VESPR polypeptides.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: May 13, 2003
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Michael R. Comeau, Robert F. DuBose, Richard S. Johnson
  • DNA encoding CD40 ligand, a cytokine that binds CD40
    Patent number: 6410711
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: June 25, 2002
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson, Arvia E. Morris, Jeffrey T. McGrew
  • Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells
    Patent number: 6391637
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor. Also disclosed are methods of simulating hybridoma cells to increase monoclonal antibody production by administering a CD40 ligand polypeptide that stimulates B cell proliferation.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: May 21, 2002
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson